Macrogenics (MGNX) Preferred Shares (2012 - 2013)
Macrogenics (MGNX) reported Preferred Shares of $73646.0 for Q3 2013, little changed quarter-over-quarter from $73646.0 in Q4 2012.
Macrogenics (MGNX) Preferred Shares (2012 - 2013) Analysis & Trends
Macrogenics (MGNX) has 2 years of Preferred Shares data on file, last reported at $73646.0 in Q3 2013.
- Preferred Shares for Q3 2013 came in at $73646.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2013 was $73646.0 (changed N/A YoY), and the FY2012 annual result was $73646.0, changed N/A from the prior year.
- Preferred Shares held at $73646.0 in Q3 2013 per MGNX's latest filing, from $73646.0 in the prior quarter.
- Over five years, Preferred Shares peaked at $73646.0 in Q4 2012 and troughed at $73646.0 in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 73,646.00 |
| Dec 31, 2012 | 73,646.00 |